HCPCS Level II
Q2058
Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
Codes near Q2058
These sit next to Q2058 in the CMS Level II file. All Q codes
- Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q3001Radioelements for brachytherapy, any type, each
- Q3014Telehealth originating site facility fee
- Q3027Injection, interferon beta-1a, 1 mcg for intramuscular use
- Q3028Injection, interferon beta-1a, 1 mcg for subcutaneous use
- Q3031Collagen skin test
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 83047-0410-04 | Aucatzyl | Autolus, Inc | 2 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.